Majors
101 IP cases indexed. Covers patent matters.
Cases Presided Over
101 cases indexed | Page 3 of 4
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB has instituted an inter partes review of Inari Medical’s 11,974,910 patent covering clot‑removal systems. Imperative Care successfully demonstrated a reasonable likelihood of unpatentability on multiple claims, prompting full‑scale review.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s 11,865,291 B2 hemostasis valve patent after Imperative Care showed a reasonable likelihood of success. All 16 challenged claims are now subject to trial.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s hemostasis valve patent after finding Imperative Care’s petition shows a reasonable likelihood of success on at least one claim.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB granted institution of an IPR against Inari Medical’s 11,969,333 patent covering intravascular clot‑removal systems. Petitioner Imperative Care showed a reasonable likelihood of success on at least one claim, prompting the Board to institute review on all challenged claims.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB granted institution of an IPR on Inari Medical’s 12,109,384 patent covering hemostasis valves. All nine claims are under review based on anticipation and obviousness arguments centered on the Schaffer reference and related prior art.
Ascentcare Dental Products, Inc. v.Solmetex, LLC
The PTAB denied Ascentcare Dental Products' IPR petition against Solmetex, LLC's dental device patent due to procedural timing issues. The Board found the patent was a post-AIA patent and the petition was filed too early.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
Imperative Care secured institution of an IPR against Inari Medical’s hemostasis‑valve patent covering claims 1‑9. The Board found a reasonable likelihood of unpatentability based on anticipation and obviousness over Schaffer and related references.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB has instituted an inter partes review of Inari Medical’s hemostasis valve patent after finding Imperative Care’s petition shows a reasonable likelihood of success. The review will cover claims 1‑9 and is based on anticipation and obviousness grounds over Schaffer, Hartley, and Eller references.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB held that Imperative Care’s challenge to Inari Medical’s hemostasis valve patent succeeded, finding all nine claims unpatentable under §§ 102 and 103 based on prior‑art references Schaffer, Hartley, Eller, and Garrison.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB held that all nine claims of Inari Medical’s hemostasis valve patent are unpatentable, finding anticipation and obviousness over Schaffer and combinations with Hartley, Eller, and Garrison.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB held that all nine claims of Inari Medical’s hemostasis‑valve patent are unpatentable, finding anticipation and obviousness over Schaffer, Hartley, Eller and Garrison references.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s 11,554,005 B2 catheter aspiration patent after Imperative Care showed a reasonable likelihood of success on at least one claim. The review covers all 15 claims and four obviousness grounds involving Garrison, Schaffer, Hartley, and Eller references.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
Imperative Care challenged Inari Medical’s 11,844,921 B2 hemostasis valve patent. The PTAB found a reasonable likelihood of unpatentability and instituted inter partes review on all 18 challenged claims.
Alamar Biosciences, Inc. v.Olink Proteomics AB et al.
Alamar Biosciences challenged Olink Proteomics' patent on grounds of obviousness (103), leading the PTAB to institute proceedings for claims 1-20. The Board found sufficient evidence that at least some claimed inventions are unpatentable, initiating a trial phase.
Integrated DNA Technologies, Inc. et al. v.Tecan Group AG
Integrated DNA Technologies challenged Tecan Genomics's NGS patent (9546399) on grounds of anticipation and obviousness over prior art references Iafrate and Kivioja. The PTAB instituted the IPR, finding a reasonable likelihood that at least one claim is unpatentable under 35 U.S.C. § 103 over Iafrate and Kivioja.
Integrated DNA Technologies, Inc. et al. v.Tecan Group AG
The PTAB instituted the IPR, finding a reasonable likelihood of unpatentability based on obviousness over Iafrate and Kivioja for key NGS claims. The Board also provided definitive claim constructions for 'indexing site' and 'identifier site.'
Integrated DNA Technologies, Inc. et al. v.Tecan Group AG
The PTAB granted institution for an IPR challenging claims 1-16 of a nucleic acid analysis patent, finding reasonable likelihood of success. The Board rejected the Patent Owner's motion to deny based on prior art similarity, allowing the technical merits of anticipation and obviousness over Kivioja and Bielas to proceed to trial.
Imperative Care, Inc. v.Inari Medical, Inc.
Imperative Care challenges Inari Medical's hemostasis valve patents under grounds of anticipation and obviousness. The Board construed the key term 'filament' to require flexibility, which influenced its initial assessment of the claims. Institution was granted, setting the stage for a full trial on infringement and validity.
Padagis US LLC et al. v.Neurelis, Inc.
Padagis US LLC successfully petitioned to challenge Neurelis, Inc.'s nasal drug formulations patent (8895546) under 35 U.S.C. § 103. The PTAB institution decision allows Padagis to proceed with the unpatentability arguments against all 22 claims.
Padagis US LLC et al. v.Neurelis, Inc.
Padagis US LLC successfully challenged claims 1-18 of Neurelis, Inc.'s patent under grounds of obviousness (103) and lack of written description (102). The Board found a reasonable likelihood that the invention is unpatentable, based on combining prior art references Gwozdz and Meezan.
Padagis US LLC et al. v.Neurelis, Inc.
Padagis US LLC successfully challenged Neurelis, Inc.'s patent claims covering nasal drug delivery formulations. The Board found a reasonable likelihood of prevailing on multiple grounds, leading to the institution of the IPR.
CSPC Pharmaceutical Group Limited et al. v.Ipsen Biopharm Ltd. et al.
The PTAB institution decision in this oncology IPR upheld the patent claims against numerous prior art references related to FOLFIRINOX and nanoliposomal irinotecan. The Board adopted a specific claim construction defining 'treatment' as requiring more than a de minimis therapeutic benefit for the patient.
Valneva Austria GMBH v.Takeda Vaccines, Inc.
Valneva Austria GMBH successfully convinced the PTAB to institute IPR proceedings against Takeda Vaccines regarding a vaccine patent. The Board found a reasonable likelihood that several claims are unpatentable over combinations of prior art, specifically citing evidence related to fetal protection and antibody transfer.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
Imperative Care successfully challenged the patentability of Inari Medical's hemostasis valve claims before the PTAB, leading to institution on grounds of anticipation and obviousness. The Board focused heavily on claim construction, ultimately defining 'filament' as a flexible length of material necessary for the device function. This decision sets important precedent regarding functional limitations in medical device patents.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
Imperative Care successfully met the institution burden in its IPR against Inari Medical's '333 patent, establishing a reasonable likelihood of prevailing on key claims. The Board found that combining prior art references like Laub and Garrison renders the claimed thromboembolism treatment systems obvious under 103.
Imperative Care, Inc. v.INARI MEDICAL, INC.
Imperative Care has successfully instituted an IPR against Inari Medical’s 11,844,921 B2 hemostasis valve patent, asserting unpatentability under §§102 and 103 based on Schaffer, Hartley, and Eller. The Board found a reasonable likelihood of success and ordered review of all challenged claims.
Imperative Care, Inc. v.INARI MEDICAL, INC.
The PTAB instituted an inter partes review of Inari Medical’s 11,554,005 B2 embolism‑treatment patent after finding Imperative Care’s obviousness arguments sufficiently persuasive.
Garmin International, Inc. v.Cardiacsense LTD
Garmin and Cardiacsense settled their IPR dispute over patent 7,980,998, leading the PTAB to terminate the proceeding without a final decision.
Imperative Care, Inc. v.Inari Medical, Inc.
Imperative Care has successfully instituted an inter partes review of Inari Medical’s 11,697,011 hemostasis valve patent, asserting anticipation and obviousness over three prior‑art references. The Board found a reasonable likelihood of unpatentability on at least one claim and ordered the trial to proceed.
Imperative Care, Inc. v.Inari Medical, Inc.
The PTAB instituted an inter partes review of Inari Medical’s 11,844,921 B2 hemostasis valve patent after Imperative Care showed a reasonable likelihood of success. All challenged claims (1‑7, 9‑10, 15‑18, 20‑24) are now under review.
Facing a similar IP matter?
Arctic Invent is a specialist IP firm with deep litigation expertise across India, EU, US, and UK. Our team uses data-driven strategy to build stronger cases.